

Transparency notification FMR LLC

Brussels (Belgium), 16 June 2025 – 20:00 (CEST) – Regulated information

1. Summary of the notification

Pursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it received a transparency notification from FMR LLC. (having its registered office at The Corporation Trust Center, 1209 Orange Street, Wilmington, New Castle County, Delaware, 19801, U.S.A.) on 12 June 2025.

FMR LLC., notified that, following a disposal of UCB shares with voting rights by its affiliates, its shareholding in UCB SA decreased and crossed downwards the 7,5% threshold on 6 June 2025.

On 6 June 2025, FMR LLC. (taking into account the holding of its affiliates) owned 13,802,069 UCB shares with voting rights, representing 7.10% of the total number of shares issued by the company (194,505,658), versus 7.52% (14,617,221 UCB shares) in the previous notification dated 19 April 2024.

2. Content of the notification

- **Reason for the notification:** Acquisition or disposal of voting securities or voting rights.
- **Notification by:** A parent undertaking or a controlling person.
- **Persons subject to the notification requirement:**

Name	Address (for legal entities)
FMR LLC	The Corporation Trust Center, 1209 Orange Street, Wilmington, New Castle County, Delaware, 19801.

- **Date on which the threshold is crossed:** 6 June 2025.
- **Threshold crossed (in %):** 7.5%.
- **Denominator:** 194,505,658.

- **Notified details**

A) Voting rights	Previous notification	After the transaction			
		# of voting rights		% of voting rights	
	Linked to securities	Not linked to securities	Linked to securities	Not linked to securities	
0					
2,003,849	2,044,956		1.05%		
10,120,497	10,048,117		5.17%		
1,438,605	993,242		0.51%		
662,255	514,366		0.26%		
129,700	200,782		0.10%		
262,315	607		0.00%		
Subtotal	14,617,221	13,802,069	7.10%		
TOTAL		13,802,069	0	7.10%	0.00%

B) Equivalent financial instruments	After the transaction					
	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement
TOTAL				0	0.00%	

TOTAL (A & B)	# of voting rights	% of voting rights
CALCULATE	13,802,069	7.10%

- **Chain of controlled undertakings through which the holding is effectively held**

FIAM LLC and Fidelity Institutional Asset Management Trust Company are controlled by FIAM Holdings LLC.

FMR Investment Management (UK) Limited is controlled by Fidelity Management & Research Company LLC.

Strategic Advisers LLC is controlled by Fidelity Advisory Holdings LLC.

Fidelity Management Trust Company is controlled by FMTC Holdings LLC.

FIAM Holdings LLC, Fidelity Management & Research Company LLC, FMTC Holdings LLC, Fidelity Advisory Holdings LLC are controlled by FMR LLC.

FMR LLC is not a controlled undertaking.

- **Additional information**

The holdings attributed to the entities mentioned in heading 10 of the notification arise from holdings of various undertakings for collective investment that are managed by FIAM LLC, Fidelity Institutional Asset Management Trust Company, Fidelity Management & Research Company LLC, Fidelity Management Trust Company, FMR Investment Management (UK) Limited and Strategic Advisers LLC each of which are entities that are subsidiaries of and controlled by FMR LLC. The entities mentioned in heading 10 are the discretionary investment managers and exercise the voting rights at their discretion in the absence of specific instructions. Trigger due to changes in the voting delegation.

3. Further information

This press release and the detailed transparency notification are available on UCB SA/NV's website via the following [link](#).

An updated overview of the UCB SA/NV large shareholdings will be available on UCB SA/NV's website via the following [link](#).

For further information, contact UCB:

Investor Relations

Antje Witte

T +32 2 559 94 14

antje.witte@ucb.com

Corporate Communications

Laurent Schots

T+32 2 559 92 64

laurent.schots@ucb.com

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 9 000 people in approximately 40 countries, the company generated revenue of € 6.1 billion in 2024. UCB is listed on Euronext Brussels (symbol: UCB).